leech therapy
PreclinicalBiologic
leech therapy is one of 39 biologic programs targeting TED. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in TED
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Scemblix
NovartisApproved
Alecensa
RocheApproved
Calquence
AstraZenecaPhase 3
Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Golytely
BayerPhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Fludara
SanofiPhase 2
Eliquis
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
TED1 trial
Investigation of Oxidant-antioxidant Status in Patients Treated With Hirudotherapy
Completed·—·N/A·NCT05438901·12,317,546 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for leech therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details